Quantcast

Latest Hematological malignancy Stories

2014-05-31 08:20:48

Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology RARITAN, N.J., May 31, 2014 /PRNewswire/ -- Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of single-agent ibrutinib (IMBRUVICA(®)) suggest continued durable responses in patients with treatment-naive (TN) or relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to data...

2014-05-29 12:28:32

Partnership Set to Raise $250,000 and Provide 12,000+ Hours of Tutoring Services WHITE PLAINS, N.Y., May 29, 2014 /PRNewswire-USNewswire/ -- While extraordinary progress has been made in treating childhood leukemia and other pediatric cancers in recent years, critical attention must also be paid to the educational and emotional challenges facing kids re-entering school after treatment. The Leukemia & Lymphoma Society (LLS) and Sylvan Learning are partnering to raise funds and...

2014-05-28 23:16:46

TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014 Tragara Pharmaceuticals, Inc. today announced the preliminary results of new preclinical research showing the activity of TG02, the company's unique oral cyclin dependent kinase (CDK) inhibitor, in chronic lymphocytic leukemia (CLL). Researchers at The Ohio State University demonstrated that TG02 is highly active in CLL cells derived...

2014-05-22 16:26:35

The Leukemia & Lymphoma Society and Oregon Health & Sciences University forged Beat AML collaboration to find effective therapies for acute myeloid leukemia patients WHITE PLAINS, N.Y., May 22, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced a $4 million commitment by the Harry T. Mangurian, Jr. Foundation to support a groundbreaking collaboration between LLS and with Brian Druker, M.D., of Oregon Health and Science University to "Beat...

2014-04-29 23:11:40

CML-IQ delivers timely, accurate information to help people make informed decisions. Montreal, QC (PRWEB) April 29, 2014 Every day in North America, about 16 people are diagnosed with a form of blood cancer called chronic myelogenous leukemia (CML). This disease is characterized by an abnormal proliferation of white blood cells, which results in bruising, a swollen spleen and bleeding complications. Until recently, life expectancy was only a few years for people diagnosed with CML. That...

2014-04-22 23:00:54

Civic Duty, cofounded by Julian Omidi and Dr. Michael Omidi, is donating to the Leukemia & Lymphoma Society’s Man and Woman of the Year campaigns. Those in the Sacramento area are invited to also support this worthy charity by attending a special art auction and show with performance painter David Garibaldi on April 24, 2014, with all proceeds going to help fund new research in hopes of curing this devastating cancer. (PRWEB) April 22, 2014 Civic Duty applauds the tireless...

2014-04-13 23:01:08

Transparency Market Research Report Added "Blood Disease Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database. Browse Full Report: http://www.transparencymarketresearch.com/blood-disease-treatment-drugs.html. Albany, New York, USA (PRWEB) April 13, 2014 Blood comprises of red blood cells, white blood cells, plasma and platelets. Sometimes, people might be affected with different types of blood disorders and...

2014-03-27 08:35:29

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/48gc9x/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Treating Refractory Hematological Malignancies" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable...

2014-03-26 08:23:02

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pt8tl4/treating ) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer through innovative drug development strategies have...

2014-03-26 08:22:56

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lnx8jm/treating ) has announced the addition of the "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma", provides an overview of the therapies for Multiple Myeloma (Newly...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related